Incidence of nephrogenic systemic fibrosis at two large medical centers.

PURPOSE To determine the incidence and associated risk factors of nephrogenic systemic fibrosis (NSF) in patients who undergo gadolinium-based contrast agent (GBCA)-enhanced magnetic resonance (MR) imaging. MATERIALS AND METHODS Institutional review board approval was obtained for retrospective review of the medical records from two hospitals to identify all cases of biopsy-confirmed NSF and all patients administered a GBCA from January 1, 1997, to June 30, 2007. Informed patient consent was not required. The incidence of NSF was calculated for patients who received a standard dose of GBCA, patients who received a high dose, and subgroups of patients with renal impairment. RESULTS Fifteen patients developed NSF after gadolinium-enhanced MR imaging. All of them had an estimated glomerular filtration rate (eGFR) lower than 30 mL/min, and 11 had acute renal failure or acute deterioration of chronic renal failure. The incidence of NSF after gadolinium-enhanced MR imaging without screening for renal function was zero of 74,124 patients with the standard dose of GBCA and 15 (0.17%) of 8997 patients with the high dose (P < .001). The NSF incidence associated with a high dose of GBCA increased to 0.4% in patients in a chronic hemodialysis program and to 8.8% in those who had an eGFR lower than 15 mL/min but were not undergoing hemodialysis (P < .001). The NSF incidence in the patients with acute renal failure who received a high dose when their creatinine level was increasing was 19% (11 of 58 patients) when hemodialysis was delayed for longer than 2 days. More patients with NSF had proinflammatory events, and compared with patients without NSF, these patients had lower pH, younger age, lower eGFR, elevated serum phosphorus levels, and a longer delay between GBCA injection and hemodialysis. CONCLUSION For patients with an eGFR lower than 15 mL/min, hemodialysis helped to prevent NSF. For patients with an eGFR lower than 30 mL/min who received a high dose of GBCA, acute renal failure, delayed hemodialysis after contrast agent injection, proinflammatory events, and hyperphosphatemia were associated with increased risk of NSF.

[1]  A. Oto,et al.  Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. , 2008, AJR. American journal of roentgenology.

[2]  H. Thomsen,et al.  High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent , 2008, Investigative radiology.

[3]  Diego R. Martín,et al.  Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. , 2008, Radiology.

[4]  D. Tudorascu,et al.  Nephrogenic systemic fibrosis: Center case review , 2007, Journal of magnetic resonance imaging : JMRI.

[5]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  E. Kanal,et al.  Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". , 2007, AJR. American journal of roentgenology.

[7]  A. Jardine,et al.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. , 2007, Radiology.

[8]  E. Poch,et al.  Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor , 2007, The British journal of dermatology.

[9]  C. Schmid,et al.  Evaluation of the modification of diet in renal disease study equation in a large diverse population. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  Amy E. Chadwick,et al.  Nephrogenic Systemic Fibrosis with Multiorgan Involvement in a Teenage Male after Lymphoma, Ewing's Sarcoma, End-Stage Renal Disease, and Hemodialysis , 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[11]  G. Saab,et al.  Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? , 2007, AJR. American journal of roentgenology.

[12]  Sudhir V. Shah,et al.  Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. , 2007, The New England journal of medicine.

[13]  T. Grobner,et al.  Gadolinium and nephrogenic systemic fibrosis. , 2007, Kidney international.

[14]  G. Scott,et al.  Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. , 2007, Journal of the American Academy of Dermatology.

[15]  J. Jamboti.  Strong association between the use of gadolinium‐based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis , 2007, Internal medicine journal.

[16]  H. Y. Lee,et al.  Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature , 2007, Clinical and experimental dermatology.

[17]  F. Ierino,et al.  Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. , 2007, Nephrology.

[18]  John Gosbee,et al.  ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.

[19]  V. Werth,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature , 2007, International journal of dermatology.

[20]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[21]  G. Bongartz,et al.  Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? , 2007, Magnetic Resonance Materials in Physics, Biology and Medicine.

[22]  E. Kanal,et al.  Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.

[23]  K. Murphy,et al.  Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. , 2007, Journal of vascular and interventional radiology : JVIR.

[24]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[25]  S. Morcos,et al.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[26]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[27]  V. Runge,et al.  Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.

[28]  H. Thomsen.  European Society of Urogenital Radiology guidelines on contrast media application , 2007, Current opinion in urology.

[29]  H. Thomsen,et al.  Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? , 2006, Clinical radiology.

[30]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[31]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  S. Cowper,et al.  Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.

[33]  D. Siegel,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. , 2006, Journal of the American Academy of Dermatology.

[34]  F. Mendoza,et al.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. , 2006, Seminars in arthritis and rheumatism.

[35]  D. Bandyopadhyay,et al.  Nephrogenic fibrosing dermopathy: a series in a non-Western population. , 2006, Journal of the American Academy of Dermatology.

[36]  T. Greene,et al.  Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  W. Ting,et al.  Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.

[38]  J. Sayre,et al.  Trends in adverse events after IV administration of contrast media. , 2001, AJR. American journal of roentgenology.

[39]  J. J. Caro,et al.  The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis. , 1991, AJR. American journal of roentgenology.

[40]  P. Parfrey,et al.  Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. , 1989, The New England journal of medicine.